Long Term Follow up of Patients Who Were Treated With Extracorporeal Membrane Oxygenation for Pandemic Influenza A/H1N1 Induced Severe Respiratory Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01763060

Enrollment

Registered

2013-01-08

Start date

2012-10-31

Completion date

2013-10-31

Last updated

2013-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long Term Outcome

Keywords

ards, ecmo, h1n1, pandemics

Brief summary

Patients treated with Extracorporeal Membrane Oxygenation (ecmo) for severe respiratory or circulatory failure show severe long term disability due to impaired lung -, cerebral-, cognitive function and impaired quality of life. This study investigates the long term outcome of all patients who are still alive three years after ECMO treatment for severe respiratory failure during the H1N1 2009 pandemic at the Karolinska University Hospital.

Interventions

RADIATIONCT scan

BEHAVIORALCognitive function

RADIATIONMRI

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Inclusion criteria

* Survivors of ECMO treatment for influenza a/h1n1 pneumonia during 2009/2010 pandemics at the ECMO Center Karolinska

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
Lung function	3 years after ecmo treatment

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026